Australia - inglese - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - foam - excipient ingredients: propane; cetostearyl alcohol; disodium edetate; propylene glycol; butane; polysorbate 60; isobutane; sodium metabisulfite - salofalk foam enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 2000 mg - enema - excipient ingredients: sodium benzoate; carbomer 934p; disodium edetate; potassium acetate; potassium metabisulfite; xanthan gum; purified water - salofalk enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 4000 mg - enema - excipient ingredients: sodium benzoate; carbomer 934p; disodium edetate; potassium acetate; potassium metabisulfite; xanthan gum; purified water - salofalk enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 2000 mg - enema - excipient ingredients: disodium edetate; potassium acetate; purified water; xanthan gum; potassium metabisulfite; carbomer 934p; sodium benzoate - salofalk enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - granules, modified release - excipient ingredients: simethicone; aspartame; microcrystalline cellulose; triethyl citrate; colloidal anhydrous silica; citric acid; carmellose sodium; magnesium stearate; purified talc; titanium dioxide; povidone; methacrylic acid copolymer; hypromellose; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - granules, modified release - excipient ingredients: colloidal anhydrous silica; purified talc; povidone; aspartame; titanium dioxide; methacrylic acid copolymer; magnesium stearate; triethyl citrate; microcrystalline cellulose; carmellose sodium; simethicone; citric acid; hypromellose; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - balsalazide sodium, quantity: 750 mg - capsule - excipient ingredients: magnesium stearate; colloidal anhydrous silica; shellac; iron oxide yellow; gelatin; titanium dioxide; iron oxide red; iron oxide black - treatment of mild-to-moderate active ulcerative colitis and maintenance of remission, in patients who are intolerant to sulphasalazine.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - infliximab, quantity: 100 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; polysorbate 80; sucrose - rheumatoid arthritis in adults: remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in: patients with active disease despite treatment with methotrexate; patients with active disease who have not previously received methotrexate. remicade should be given in combination with methotrexate. efficacy and safety in rheumatoid arthritis have been demonstrated only in combination with methotrexate. ankylosing spondylitis: remicade is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease. psoriatic arthritis: remicade is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (dmard) therapy. remicade may be administered in combination with methotrexate. psoriasis: remicade is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. safety and efficacy beyond 12 months have not been established. crohn's disease in adults and in children and adolescents (6-17 years): remicade is indicated for the treatment of moderate to severe crohn's disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies. refractory fistulising crohn's disease: remicade is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients. ulcerative colitis in adults and in children and adolescents (6 to 17 years); remicade is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; ethanol - indications: treatment of ulcerative colitis in patients intolerant of sulphasalazine.